Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Nov 18, 2014
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • critically ill patients with expected ICU stay for more than 72 hours
- • informed consent by the patients or legal proxy
- Exclusion Criteria:
- • age \< 18
- • no informed consent by the patients or legal proxy
- • pregnancy
- • infaust prognosis
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Patients applied
Trial Officials
Steffen Weber-Carstens, MD
Principal Investigator
Charite University, Berlin, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials